Immune checkpoint inhibitors can kill cancer cells by inducing CD8-positive T cells, especially anti-CTLA4 and anti-PD-1 antibodies that have been widely used in SKCM and revolutionized its treatment (43), and it can be concluded from the previous analysis that the inflammatory features of TME are stronger in the low-risk group. The gene discussed is CTLA4; the disease is cancer.